Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Palbociclib breast cancer
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
Lead team presentation
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
Kaplan-Meier curves of progression-free survival among patients in... | Download Scientific Diagram
Japanese patients in PALOMA-2: swimmer plot of subsequent therapy in... | Download Scientific Diagram
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases - Annals of Oncology
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3 | SpringerLink
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm - Boyle - 2018 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
PALOMA-3: Overall survival (OS) with palbociclib plus fulvestrant in HR+,HER2_ ABC - YouTube
MONARCH 2: Overall survival of abemaciclib plus fulvestrant in HR+, HER2- advanced breast cancer - YouTube
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases - ScienceDirect
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Figure 2 from Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis | HTML
Progression-free survival in the PALOMA-1 study (palbociclib +... | Download Scientific Diagram
